Colorectal Cancer
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
The guideline was developed using a multidisciplinary team of oncologists in collaboration with ASCO and the SUO.
ctDNA can serve as a major independent prognostic biomarker in patients with stage III colon cancer after surgery.
The combination was shown to provide a 71% response rate, pointing to a new potential treatment for this patient population.
With an OS rate of about 80%, encorafenib and cetuximab with FOLFOX may serve as a new FDA-approved frontline regimen.
Encorafenib with cetuximab was approved by the FDA in 2024 for previously treated patients with BRAF V600E-mutant mCRC.
Dr. Kopetz elaborates on the key efficacy and safety findings, including how they compare to current standard treatments.
Dr. André elaborates on the efficacy and safety profiles of both treatments and their influence on current therapies.
Dr. Fakih elaborates on the combination's objective response rate, and how it can potentially redefine treatment paradigms.
Dr. Fakih elaborates on the Fc-enhanced design of botensilimab, and how the combination compares to prior therapies.
The study showed that favezelimab/pembrolizumab did not demonstrate a survival benefit over SOC.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.